This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Korn, K.
Right arrow Articles by Schmidt, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Korn, K.
Right arrow Articles by Schmidt, B.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2003, p. 3559-3565, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3559-3565.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Quality Control Trial for Human Immunodeficiency Virus Type 1 Drug Resistance Testing Using Clinical Samples Reveals Problems with Detecting Minority Species and Interpretation of Test Results

Klaus Korn, Heide Reil, Hauke Walter, and Barbara Schmidt*

Institute of Clinical and Molecular Virology, German National Reference Centre for Retroviruses, University of Erlangen-Nürnberg, D-91054 Erlangen, Germany

Received 9 October 2002/ Returned for modification 12 March 2003/ Accepted 18 May 2003

Between January and March 2000, a quality control panel for human immunodeficiency virus (HIV) drug resistance testing was analyzed by 20 laboratories in five countries. The panel consisted of three clinical samples with different drug resistance genotypes and phenotypes and one HIV-negative plasma. Participants were asked to report the methods used for amplification and sequencing, a list of drug resistance-associated mutations that were detected in the protease and reverse transcriptase of each sample, and an interpretation concerning the susceptibility or resistance to 14 antiretroviral drugs. A total of 22 genotypic data sets were generated, which showed an overall good technical quality except for three participants, who failed to report key mutations for drug resistance. Problems were encountered in three respects: (i) resistant minorities of L90M in the protease, which were determined to about 12% by real-time amplification, were only detected by one-fourth of the participants; (ii) newly described resistance mutations were frequently not reported; and (iii) interpretations of drug resistance-associated mutations varied widely, in particular for protease inhibitors. In some cases, different interpretations were caused by differences in the detection of resistant minorities, but even for the same genotypic profile, interpretations varied considerably. Similar discrepancies were revealed if current Web-based interpretation systems were used to predict drug resistance for samples of the proficiency panel. This indicates that a consensus for the interpretation of drug resistance-associated mutations is urgently needed.

* Corresponding author. Mailing address: Institute of Clinical and Molecular Virology, German National Reference Centre for Retroviruses, University of Erlangen-Nürnberg, Schlossgarten 4, D-91054 Erlangen, Germany. Phone: 49-9131-85-24010. Fax: 49-9131-85-26485. E-mail: baschmid{at}viro.med.uni-erlangen.de.

Journal of Clinical Microbiology, August 2003, p. 3559-3565, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3559-3565.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kajiwara, K., Kodama, E., Sakagami, Y., Naito, T., Matsuoka, M. (2008). Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. J. Clin. Microbiol. 46: 792-795 [Abstract] [Full Text]  
  • Snoeck, J., Kantor, R., Shafer, R. W., Van Laethem, K., Deforche, K., Carvalho, A. P., Wynhoven, B., Soares, M. A., Cane, P., Clarke, J., Pillay, C., Sirivichayakul, S., Ariyoshi, K., Holguin, A., Rudich, H., Rodrigues, R., Bouzas, M. B., Brun-Vezinet, F., Reid, C., Cahn, P., Brigido, L. F., Grossman, Z., Soriano, V., Sugiura, W., Phanuphak, P., Morris, L., Weber, J., Pillay, D., Tanuri, A., Harrigan, R. P., Camacho, R., Schapiro, J. M., Katzenstein, D., Vandamme, A.-M. (2006). Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. Antimicrob. Agents Chemother. 50: 694-701 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»